In MS, we found that KCNQ3 and KCNQ5 were downregulated in L2–6 ENs (Figure 2B and Supplemental Table 6), specifically in patients with long disease duration (Figure 2D and Supplemental Table 7). Here, KCNQ5 is linked to myeloid sarcoma.